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Mesenchymal stem/stromal cells (MSC) within the bone marrow (BM) are vitally important in forming 
the microenvironment, supporting haematopoiesis after myeloablative chemotherapy. MSC are known 
to be damaged phenotypically and functionally by chemotherapy, however, to our knowledge the 
persistence of genotoxic effects of chemotherapy on the BM microenvironment has not been studied. 
We therefore aimed to evaluate genotoxic effects of chemotherapy on the BM both in-vitro and in-vivo, 
using the comet and micronucleus assays, focussing on the persistence of DNA lesions which may 
contribute to complications in the patient. The MSC cell line (HS-5) and primary cord blood 
mononuclear cells (CBMNC; a source of undamaged DNA) were exposed to the chemotherapeutic 
agent cyclophosphamide (CY) within a physiologically relevant in vitro model.  CY treatment resulted 
in significant increases in CBMNC DNA damage at all time points tested (3-48hr exposure). Similarly, 
HS-5 cells exposed to CY exhibited significant increases in DNA damage as measured by the comet 
assay, with increased numbers of abnormal cells visible in the micronucleus assay. Additionally, even 
48hrs after removal of 48hr CY treatment, DNA damage remains significantly increased in treated cells 
relative to controls. In patients treated with chemotherapy for haematological malignancy highly 
significant increases in damaged DNA were seen in BM cells isolated from one individual one year 
after completion of therapy for acute leukaemia compared with pre-treatment (p<0.001).  Similarly, two 
individuals treated 7 and 17 years previously with chemotherapy exhibited significant increases of 
damaged DNA in MSC compared with untreated age- and sex-matched controls (p<0.05). Unlike 
haematopoietic cells, MSC are not replaced following a stem cell transplant. Therefore, long-term 
damage to MSC may impact on engraftment of either allogeneic or autologous transplants. 
Additionally, persistence of DNA lesions may lead to genetic instability, correlating with the significant 




Mesenchymal stem/stromal cells (MSC) are the supportive stem cells of the bone marrow 
microenvironment, contributing to the bone marrow (BM) stroma and playing a vitally important role in 
supporting haematopoiesis, both through cell-cell contact and secretion of soluble factors (1,2). MSC have 
previously been shown to be phenotypically and functionally damaged by chemotherapy, particularly by high-
dose chemotherapy administered prior to a stem cell transplant (SCT) as a potential cure for haematological 
malignancy (3,4,5,6,7). However, the exact nature of this cellular damage is poorly characterised. In addition, 
whilst haematopoietic cells are replaced during a SCT, MSC are not and remain of host origin (8,9). Therefore, 
if MSC are severely damaged by the SCT preparative regimen, this may be permanent, particularly if effected 
at the DNA level. Indeed, functional damage to BM stroma is thought to be slow to repair (10), and in one study 
was shown to be severe and irreversible, with the ability to support haematopoiesis being completely recoverable 
only in children under 4 years of age (11). 
Clinically, damage to MSC may result in graft failure, seen following a significant number of transplants 
(12). Damage induced at the DNA level may also increase the risk of genetic instability and development of 
malignancies (13). Therapy-related primary malignancies are seen in a significant proportion of chemotherapy-
treated individuals, and commonly arise within the BM, manifesting as therapy-related myelodysplastic 
syndrome or acute myeloid leukaemia (14,15,16).  
We and others, have previously reported cellular damage to MSC from chemotherapy, both in-vitro and 
in-vivo (17,18), focussing on impact on differentiation, morphology, colony forming units and premature ageing 
(3,5,6,7,11,19,20). The genotoxic impact of chemotherapy has previously been reported in haematopoietic 
progenitor cells (21,22), however, this has not been studied within the MSC population and the BM 
microenvironment. With its critical role in supporting haematopoiesis, damage to the BM microenvironment 
may have significant consequences haematologically, particularly given that these cells cannot be replaced 
therapeutically (8,9). Furthermore, the fact that haematopoietic cells largely succumb to chemotherapy whereas 
MSC do not, genotoxic outcomes to the BM microenvironment arguably may have a more important impact on 
patient outcome. 
 4 
Therefore, this study aimed to further characterise genotoxic damage to the supportive BM 
microenvironment from chemotherapy, including longer-term persistence of lesions, which may have 
considerable clinical impact. 
Materials and Methods 
All reagents were obtained from Sigma-Aldrich, Dorset, UK, unless otherwise specified. 
Sample collection 
Iliac crest BM samples were obtained from the Royal United Hospital, Bath, from patients undergoing 
BM aspirations for the diagnosis of haematological malignancies or for therapy monitoring purposes, with donor 
consent and National Research Ethics Service (NRES) approval (REC approval numbers: Southmead 048/01, 
BA504). BM was collected by medical staff into sterile tubes containing 1000IU heparin. Details of samples 
analysed in this study are shown in Table I.  
We were unable to access BM MSC from healthy young donors, due to ethical considerations of the 
invasiveness of the procedure. As residual DNA damage amasses naturally with age (23), we therefore utilised 
cord blood (CB) samples as a source of MNC, of which MSC constitute a proportion. CB was obtained from 
healthy, full-term deliveries at Southmead Hospital, Bristol, with NRES approval and donor consent. 
Additionally, as a further comparison, an MSC cell line (HS-5) was also utilised to study effects of 
chemotherapy in vitro.  
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Untreated samples Chemotherapy-treated samples 
UPI 59 – 65yr old male.  
Unknown reason for BM aspirate 
UPI 82 – 63yr old male, myeloma. Treated with VAD, 
high-dose melphalan and thalidomide (6 cycles) with 
autologous transplant. All 7 years prior to BM aspirate 
UPI 143 – 64yr old male. 
Persistent thrombocytopaenia 
UPI 164 – 63yr old male, low grade lymphocytic 
lymphoma. Treated with mitoxantrone, chlorambucil and 
prednisolone (6 cycles). Last treatment 17 years prior to 
BM aspirate 
UPI 150 – 50yr old female. 
 Query acute myeloid leukaemia 
(AML) 
UPI 193 – 51yr old female (previous sample UPI 150). 
AML. Treated with ADE and myelotarg (2 cycles) and 
MACE. Last treatment 1 year prior to BM aspirate 
Table I. Clinical details of bone marrow samples used within this study. Two untreated and chemotherapy-treated samples were 
age- and sex-matched for analysis (UPI numbers 59, 82, 143 and 164). One individual was assessed prior to, and one-year 
following completion of chemotherapy (UPI numbers 150 and 193 respectively). UPI = unique patient identifier, assigned to each 
sample at the time the aspirate is taken to ensure anonymity within the study. VAD = vincristine, doxorubicin and 
dexamethasone. ADE = daunorubicin, cytosine arabinoside and etoposide. MACE = amasacrine, cytosine arabinoside and 
etoposide. 
 
Isolation of mononuclear cells  
Mononuclear cells (MNC) were isolated from BM and CB samples by lymphoprep separation, as 
described previously (5). Samples were diluted 1:1 with low glucose Dulbecco’s Modified Eagle’s Medium 
(DMEM) and layered onto lymphoprep (Axis Shield, Cambridgeshire, UK; density 1.077+/-0.001g/ml). 
Following centrifugation (600 x g for 30mins), the buffy coat layer was harvested, washed in DMEM and then 
cultured in MSC medium (DMEM containing 10% foetal calf serum (FCS) selected for optimal MSC growth 
(Stem Cell Technologies, Grenoble, France) containing 100U penicillin and 0.1mg streptomycin/ml). MNC 
from BM samples were seeded in primary culture to enable expansion of the MSC population (see ‘MSC 
culture’). MNC from CB were used immediately in in-vitro chemotherapy treatment experiments (see 
‘chemotherapeutic treatment of CB MNC and HS-5 cells’) 
MSC culture 
MSC were cultured from bone marrow aspirates as described by (24). Briefly, primary cultures (1x107 
MNC per T-25 flask in MSC medium) were incubated at 37°C in 5% CO2 and maintained by weekly demi-
depletion of medium until 70% confluent. Cultures were then passaged using 0.25% trypsin and reseeded at 
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first passage at 1x105 cells per flask. Weekly demi-depletion of medium and passaging enables isolation of MSC 
utilising plastic adherence (25).  
MSC were immunophenotyped at the end of second passage (see ‘immunophenotyping of MSC’) before 
being cryopreserved in DMEM, containing 25% FCS and 10% DMSO in the vapour phase of liquid nitrogen 
until required for comet assay.  
HS-5 culture 
HS-5 cells were obtained from American Type Culture Collection (Middlesex, UK) and cultured in 
high glucose DMEM, supplemented with 10% FCS. Cultures were maintained by sub cultivation at a ratio of 
1:3, with medium replaced every 2-3 days. Experiments were performed on low passage number cells (<10 
passages). 
Immunophenotyping of MSC 
Immunophenotyping was performed at the end of second passage to confirm presence of a pure 
population of MSC, according to International guidelines (26). Cells (1x105) were stained for surface markers 
by labelling with anti-CD105 PE/anti-CD90 FITC (AbD Serotec, Oxford, UK and BD Biosciences Oxford, UK 
respectively), anti-CD73 PE/anti-CD45 FITC (BD Biosciences and Dako, Cambridgeshire, UK, respectively), 
anti-CD44 PE/anti-CD19 FITC (BD Biosciences), anti-CD14 PE/anti-CD34 FITC (BD Biosciences and AbD 
serotec respectively), anti-CD29 PE and anti-CD166 PE, and isotype controls (all BD Biosciences) for 45mins 
on ice, followed by flow cytometry analysis (FACS Vantage SE using Cell Quest ™ software, Becton 
Dickinson, Oxford, UK).  Cells were gated to exclude debris and dead cells, with 10000 gated events analysed. 
All further experiments using MSC were performed immediately after immunophenotyping at the end of second 
passage. 
Chemotherapeutic Treatment of CB MNC and HS-5 cells 
Cells were seeded in 6-well plates (2x106 cells per well for CB MNC) or in 24-well plates (2.5x104 cells 
per well for HS-5) and exposed to 500μM cyclophosphamide (CY) either in the presence of filtered S9 extract 
(0.4mg/ml) (27), or HepG2 liver spheroids (17) to enable conversion of CY to active metabolites. Control wells 
containing cells only, cells + S9, cells + CY, cells + HepG2 spheroids (SPH) were also utilised. Treatments 
were added for 3-48 hours, mimicking the treatment time in vivo when CY is given 2 days prior to SCT (28). A 
shorter period of 3hrs was also used as S9 is known to be toxic over extended periods in culture (29). Comet 
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assays were performed immediately after removal of CY at 3hrs and 48hrs exposure, as well as up to 48hrs after 
removal of 48hr CY treatment, to investigate the persistence of genotoxicity after removal of the agent. At all 
time points where genotoxicity assays were performed, corresponding cytotoxicity was determined by the 
calculating relative increase in cell count (RICC) as detailed by Fellows et al., (30). 
HepG2 spheroid culture 
HepG2 hepatoma cells (European Collection of Authenticated Cell cultures, Porton Down, Salisbury, 
UK) were cultured in high glucose DMEM, with 10% FCS, 100U penicillin and 0.1mg streptomycin/ml, 2mM 
L-glutamine and 1% non-essential amino acids, at 37°C with 5% CO2. Confluent cells were trypsinised, seeded 
into a 6-well plate (3x106 cells per well) and incubated on a gyrotatory shaker at 83rpm for 24hrs and 79rpm 
thereafter to enable the formation of spheroids. Medium was demi-depleted every second day and maturity 
reached after 6 days of culture (31). 
Alkaline comet assay 
To determine levels of DNA damage, alkaline comet assays were performed following the 
manufacturer’s instructions (AMSBIO, Abingdon, UK). Briefly, cells were harvested by gentle scraping, 
washed twice with cold PBS and enumerated. Samples were kept on ice at all times and protected from light to 
prevent further DNA damage. Untreated cells and positive controls (100µM H2O2 for 20-30mins on ice) were 
always processed simultaneously. Cells were resuspended in ice cold PBS (4x105/ml), of which 25µl was then 
combined with 250µl molten agarose and 50µl spread onto the comet slide. Lysis and alkali unwinding was 
performed for 1hr each, with electrophoresis similarly performed for 1hr (1V/cm); ensuring the tank remained 
on ice and protected from light. Slides were stained with SYBR green at 4˚C in the dark for 5 minutes, and 
visualised using a Nikon TE300 inverted microscope with images taken using a Roper Scientific camera and 
Image-Pro Plus software.  Comet assay images were analysed for % DNA in the tail, using Comet Assay V 
software (Perceptive Instruments, Bury St Edmunds, UK). 
Micronucleus Assay 
Immediately after 48hr in-vitro chemotherapy treatment and again 48hrs later, CBMNC and HS-5 cells 
were analysed using the micronucleus assay. Cells (2x104) were harvested, washed in PBS and cytospun for 
10mins at 300g. Slides were air dried, fixed in 100% methanol for 8mins, then dipped in fresh phosphate buffer 
(0.66%w/v K2HPO4 and 0.32%w/v NaH2PO4, pH6.4-6.5), before being stained in acridine orange solution 
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(12mgs in 100mls of the previous phosphate buffer). After staining for 1min, slides were transferred back into 
the initial phosphate buffer for 10mins, followed by transfer into a new batch of the same buffer for a further 
15mins. Following air drying, slides were protected from light and examined using a Nikon TE300 inverted 
microscope with images taken using a Roper Scientific camera and Image-Pro Plus software. Fifty images were 
taken for each treatment, and all cells within each field of view scored for morphology, including identification 
of 1, 2 or 3 micronuclei, bi-nucleated, multinucleated, lobed, blebbed or apoptotic cells.  
Statistical analysis 
A minimum of 30 comets were scored in the initial time course assay and a minimum of 50 comets 
scored thereafter, with a minimum of 1000 cells scored for each treatment in the micronucleus assay as 
recommended by genotoxicology testing guidelines in place when relevant experimental work was undertaken 
(32).  
All statistical analysis was performed in GraphPad Prism 7, using Mann-Whitney test to analyse 
differences between two groups/samples, and one-way ANOVA performed for comparison of 3 or more groups, 
with significance considered to be p<0.05. 
Results 
Genotoxicity from in-vitro treatment  
Following 3hr or 48hr in-vitro CY treatment, CB samples exhibited significantly increased percentages 
of damaged DNA measured by the comet assay compared with the untreated control (Figure 1), whilst cell 
viability remained above 70% (figure 1C). Treatment with CY alone over 3hrs did not result in a significant 
difference compared with untreated controls (Figure 1A), due to CY itself being largely inactive and requiring 
hepatic metabolism. In contrast, in the presence of either S9 liver extract or HepG2 liver spheroids, a significant 
increase in DNA within the comet tail was seen compared to both untreated cells and those exposed to CY alone 
(p<0.001) (Figure 1A). It is also worth noting the increase in DNA damage seen following exposure of cells to 
S9 extract alone. S9 is known to be toxic over extended periods in culture (29), but these data indicate genotoxic 
effects within even 3hrs exposure (Figure 1A). 
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Fig 1. Assessment of DNA damage in CB MNC following in-vitro CY treatment. Percentage of DNA within the comet tail 
following 3hr (A) or 48hr (B) CY treatment in the presence of S9 extract or HepG2 liver spheroids (SPH) as a source of 
metabolism. Corresponding calculated relative increase in cell count for each treatment as an indication of cytotoxicity (C). A 
minimum of 50 comets were analysed for each treatment, with the combined data from two CB samples shown for each time 
period. All samples at both time points differ significantly from untreated cells (p<0.001) except S9 and SPH alone at 48hr. Boxes 
represent the middle 50% of data, with 10-90% of the population then encompassed by the extended lines, and outliers indicated 
by symbols. H2O2 treatment for 20-30 minutes was used as a positive control.  
 
Significant increases in numbers of DNA strand breaks are also seen after 48hr treatment of CB with 
CY in the presence of either S9 or liver spheroids, in comparison to untreated cells (p<0.001) (Figure 1B). A 
significant increase above that of cells exposed to CY alone is only seen with S9 and CY, although the 
distribution of percentage of damaged DNA is skewed towards greater damage when CY is combined with SPH. 
This is partially due to increased damage seen in cells exposed to CY alone as a result of spontaneous 
decomposition of the parent drug in aqueous conditions during extended culture periods (33). Additionally, 
DNA crosslinking by nitrogen mustards can retard comet tails (34), and thus spheroids may be more efficient 
than S9 at metabolizing CY, resulting in greater crosslinks. A time-course assay investigating extent of 
genotoxic damage to MNC from CY in vitro in combination with liver spheroids also demonstrated significant 
increases in DNA damage at all time points examined beyond 3hrs exposure (p<0.001), even up until 48hrs 
after removal of the drug (Figure 2A), whilst cell viability does not fall below 86% (Figure 2B). Even 48hrs 
after cessation of treatment genotoxicity is not statistically different to levels seen 24hrs into the 48hr treatment 
period (p>0.999).  
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Fig 2. CB MNC were exposed to CY in the presence of liver spheroids for 3hrs, 24hrs or 48hrs after which they were immediately 
analysed (A). Additionally, some cells were exposed to this treatment for 48hrs after which they were maintained in normal 
medium and genotoxic damage assessed 24hrs and 48hrs later (A). Corresponding calculated relative increase in cell count for 
each treatment as an indication of cytotoxicity (B). A minimum of 30 comets were analysed at each time point, with the combined 
data from two cord blood samples shown. All samples differ significantly from the untreated control (p<0.001) except cells 
treated for 3 hours only. Boxes represent the middle 50% of data, with 10-90% of the population then encompassed by the 
extended lines, and outliers indicated by symbols. H2O2 treatment for 20-30 minutes was used as a positive control.  
 
Similarly, following exposure of HS-5 stromal cells to CY in vitro, significant increases in DNA 
damage were seen, when treated in the presence of both S9 liver extract (p<0.001) and HepG2 liver spheroids 
(p=0.003) as a source of metabolism (Figure 3A). As with CB MNC, HS-5 DNA damage increased with 
exposure time (Figure 3B), gradually decreasing after CY was removed, but remaining higher than in untreated 
cells even 48 hours after removal of the chemotherapy. Whilst corresponding cell viability remained above 75% 
for all shorter 3hr treatments (Figure 3C), higher levels of cytotoxicity were seen over prolonged treatment 





Fig 3. HS-5 bone marrow stromal cells were exposed to CY in the presence of S9 extract or HepG2 liver spheroids as a source of 
metabolism. Percentage of DNA within the comet tail analysed immediately after 48hr treatment (A) or treated for up to 48hrs 
in the presence of HepG2 liver spheroids (SPH), with cells analysed immediately, or maintained in normal medium and genotoxic 
damage assessed 24hrs and 48hrs later (B). Corresponding calculated relative increase in cell count for each treatment as an 
indication of cytotoxicity (C and D). A minimum of 50 comets were analysed for each treatment, with the combined data from 
three independent repeats shown.. Boxes represent the middle 50% of data, with 10-90% of the population then encompassed 
by the extended lines, and outliers indicated by symbols. H2O2 treatment for 20-30 minutes was used as a positive control. 
 
A MN assay was initially performed on HS-5 immediately after removal of 48hr chemotherapy 
treatment (Figure 4A, B, E). An increase in MN were seen in cells exposed to chemotherapy either in the 
presence of S9 liver extract or HepG2 liver spheroids (data not shown). These increases then became statistically 
significant 48hrs after removal of the chemotherapy (figure 4C), for cells exposed to CY in the presence of liver 
spheroids (p=0.037). As was seen in the comet assay, S9 itself also resulted in as many abnormal cells as CY 
combined with S9, whereas HepG2 liver spheroids themselves had no effect on numbers of abnormal cells seen 
(p=0.9996).  
In addition to considering MN alone, the total number of cells exhibiting altered morphologies 
(including blebbed, multinucleated, lobed, apoptotic and binucleate with MN) was also significantly increased 
48hr after chemotherapy removal, in both those cells treated in the presence of S9 or liver spheroids (p<0.001 
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and p=0.021 respectively) (Figure 4D). In particular, blebbed cells were much more prominent following 
chemotherapy treatment, although not significantly (p>0.05). Additionally, whilst apoptosis was initially 
diminished in cells exposed to S9 for 48hrs either with or without CY (Figure 4E), it was significantly increased 
48hrs later (p=0.005 and p=0.032 respectively), whilst all other treatments remained comparable to the untreated 
control (Figure 4F).   
 13 
 
Fig 4. Following 48hr treatment with CY in the presence of S9 extract or HepG2 liver spheroids, a micronucleus assay was 
performed on HS-5 bone marrow stromal cells both at 48hrs when treatment was removed (A, B and E), and again 48hrs after 
removal of treatment (C, D and F). Examples of typical mononucleated cells seen in untreated slides are shown (A), together 
with examples of altered morphologies in cells exposed to CY and liver spheroids (B). An apoptotic cell is highlighted with a 
dashed arrow, and micronuclei highlighted by solid arrows (B). Percentage of cells with micronuclei are shown as a total of all 
cells analysed within each population (C) Total abnormal cells in each population, showing percentages of each type of 
morphology (D). Percentage of apoptotic cells at the time of treatment removal (E) and 48hrs later (F) are shown as a total of all 
cells analysed within each population. Corresponding calculated relative increase in cell count for each treatment as an indication 
of cytotoxicity (G). A minimum of 1000 cells were analysed per treatment. Data shown as mean +/- SD, combined data from 
three separate experiments at each time point tested.  
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Genotoxicity from in-vivo treatment 
All BM MSC were plastic adherent and immunophenotyped according to ISCT guidelines (26) and 
purity found to be greater than 95% (data not shown). Unfortunately, it was not possible to also perform 
differentiation studies on patient samples due to inadequate cell numbers. 
Following identification of increased DNA damage in CB cells exposed to in-vitro chemotherapeutic 
treatment, BM cells from small numbers of individuals treated previously with chemotherapy were assessed for 
genotoxicity. Particularly striking is the highly significant increase in damaged DNA seen in BM MNC from 
one individual post-treatment (p<0.001) (Figure 5). It is also noteworthy that this effect is not recent, with 
chemotherapy completed more than 1 year prior to analysis.  
 
Fig 5. Assessment of DNA damage in BM cells following in-vivo chemotherapeutic treatment. Alkaline comet assays were 
performed to assess genotoxic damage, with damaged DNA represented by the tail portion of the comet. Images (A) from a comet 
assay performed on cells isolated from samples from the same individual pre- and post- chemotherapy treatment in vivo 
(treatment details shown in Table I), with percentages of damaged DNA (B). A minimum of 50 comets were analysed for each 
sample. Columns represent the lowest 50% of cells, with the highest 50% shown by the extended line.  
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A significant increase in DNA damage is also seen in BM MSC from chemotherapy-treated patients 
compared with age- and sex-matched untreated individuals (p=0.037) (Figure 6). Similarly, this appears to be a 
long-term effect, with last treatment received 7 and 17 years prior to analysis.  
 
Fig 6. Assessment of DNA damage in BM cells following in-vivo chemotherapeutic treatment. Alkaline comet assays were 
performed to assess genotoxic damage, with damaged DNA represented by the tail portion of the comet. Representative images 
(A) from a comet assay performed on BM MSC from two age- and sex-matched untreated and chemotherapy-treated individuals 
(treatment details shown in Table I). A minimum of 50 comets were analysed for each sample, with combined data from 2 samples 
per group shown in (B), indicating percentage of DNA within the comet in untreated and treated patients. Columns represent 




Genotoxicity from in-vitro treatment 
Results seen in this study are comparable with data generated in other similar in vitro studies using other 
cell types.  Oshida et al., (35), reported genotoxic effects following exposure of the murine BM cell line, FDC-
P2 to CY in vitro in the presence of S9 preparation, where slightly higher proportions of damaged DNA were 
seen, although damage in untreated cells was also considerably higher. However, S9 was used at a higher 
concentration, and genotoxicity of S9 itself is not mentioned. Additionally, Oshida’s study (35) utilised S9 from 
rat liver, which has been shown to have much higher metabolic activity than human-derived S9 and is thus more 
likely to produce mutagenic effects (36). 
In the current study, genotoxic effects of in vitro chemotherapeutic exposure have been examined in 
CB MNC rather than BM MSC. Ideally, this should also be examined in MSC, as different cell types may differ 
in terms of sensitivity, repair capacity etc. However, due to ethical problems with obtaining BM from healthy, 
young individuals, CB MNC were used as a ‘clean’ source of DNA. Attempts were made to isolate MSC from 
CB, however, we, as others have encountered previously, found it unrealistic to isolate and culture sufficient 
cell numbers for analysis (24,37). Cord blood and haematopoietic cells are much more sensitive to 
chemotherapy than MSC, indeed with haematopoietic cells being the intended target for cytotoxic and genotoxic 
effects in the cases of haematological malignancy therapy. MSC are known to be much more resistant to the 
effects of chemotherapy, with some studies showing them to be relatively resistant to certain agents (38), 
however, functional damage has been shown with other agents (5,7). In this work, we show high viability 
following chemotherapeutic treatment and the ability to remain present both in vitro and in vivo, yet with 
considerable genotoxicity. Clinically, it is essential that these cells remain viable with their critical function to 
support haematopoiesis; nevertheless, any genotoxicity that persists may have important clinical considerations. 
As an additional comparison, the MSC cell line HS-5 was also treated with CY in vitro in the same way 
as the CB MNC cells, to enable study of a uniform population of specifically BM stromal cells. Similar trends 
were seen in both cell types following in vitro exposure, with a peak in damage seen as treatment progresses, 
and levels then decreasing once the drug was removed, although remaining higher than untreated cells at all 
time points tested. The point at which maximal damage was seen differed between the two cell types, however, 
seen at 48hrs in HS-5 (p<0.001 compared to the untreated control), and at 24hrs in CBMNC (p<0.001 compared 
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to the untreated control). This may be due to differing cell turnover times, with HS-5 doubling time calculated 
as approximately 48hrs within this study, although reported by others to take up to 72hrs (39), whilst CB MNC 
doubling time may vary widely between different donors and within different cell populations within each 
sample.  
Initially MN assays were performed on HS-5 cells immediately after removal of 48hr chemotherapy 
treatment. Subsequently, these were repeated 48hrs later after 2 calculated population doublings, as 
recommended by Kirsch-Volder et al., (27) who report optimum results if cells are harvested after 1.5-2 cell 
cycles. Data from both time points followed the same trend, with increases in MN in treated cells becoming 
statistically significant after 2 population doublings. In addition to MN, other abnormal morphologies were also 
increased in treated cells, although not significantly. Blebbed cells in particular, were increased following 
treatment, and it has been suggested that these, together with MN are important indicators for genome instability 
(40). 
Comet assay and MN are acknowledged to be robust and sensitive assays to evaluate DNA breaks, 
linked to mutagenicity. The alkaline comet assay in particular is able to detect a broad spectrum of DNA damage 
and is recommended as a first line assay due to higher sensitivity than the MN assay (41). However, the MN 
assay has the advantage of greater ease of controlling conditions and thus is a regulatory genotoxicity test, hence 
both assays were performed in conjunction in this study, with complementary results obtained.  
Whilst the HS-5 cell line represents a readily available source of relevant bone marrow stromal cells for 
this study, these cells were originally isolated from a 30-year old individual (42) and hence it is important to 
acknowledge that these will also have residual DNA damage due to unknown exposures throughout the 
individuals’ lifetime. 
Early genotoxic damage tends to arise from single strand breaks (SSB), which are short-lived lesions 
and rapidly repaired (43). SSB are the primary lesion detected by the alkaline comet assay, with virtually all 
genotoxicants producing far more SSB than double strand breaks or alkali labile sites (32). Therefore, following 
3hr incubation with CY in vitro, it is likely that some of the initial genotoxic effects seen are predominantly 
SSB, possibly caused by rapid depletion of cellular glutathione and oxidative damage induced by the metabolite 
acrolein (44). 
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Conversely, damage seen later (24hrs onwards), is likely due to repair of DNA adducts resulting in 
strand breaks as an intermediate process in base excision repair or nucleotide excision repair. Therefore, slightly 
decreased genotoxic effects seen at 48hrs onwards may be as a result of some damage having been repaired, 
although considerable quantities of DNA remain within the comet tail, even 2 days after removal of the agent, 
suggesting persistence of some lesions. Clinically, patients are routinely treated with myeloablative 
chemotherapy for 48 hours prior to a stem cell transplant (28), therefore genotoxic damage persisting beyond 
this point, as seen in this work for up to a further 48 hours, may have implications for support of incoming donor 
haematopoietic stem cells and therefore patient outcome.  
It is also possible that some heavily damaged cells have undergone apoptosis prior to analysis at later 
time points in this study, with only less extensively damaged cells undergoing repair. Indeed, >2.5% of HS-5 
cells exposed to CY alone or in the presence of liver spheroids were found to be apoptotic in the MN assay at 
48hrs, compared with only 1.7% of untreated cells. Additionally, scoring of heavily damaged cells within the 
comet assay is challenging, with some debate about how hedgehog comets should be scored and documented 
(54). 
As inferred earlier, the apparent “loss” of DNA in the comet tail can also occur where crosslinking 
agents retard the movement of DNA (46). It was evident that S9 produced larger comet tails in comparison to 
spheroids, despite our functional data favouring spheroids as a model of physiological metabolism (17,18). This 
could suggest that either spheroids balance the generation of genotoxicity by activation/deactivation of the 
parent compound whereas S9 over-estimates damage, or spheroids are more capable of the metabolic processes 
leading to crosslink formation.  Additionally, S9 is known to be cytotoxic over extended periods of time (29), 
which may have negatively impacted on results from the comet assay. It is recommended that cell viability 
should be above 70% for the assay, although there is some discrepancy over acceptable cytotoxicity levels, with 
some experts in the field allowing as low as 50% cell viability (32,45). Within this work, relative increase in 
cell count (RICC) has been used as a measure to estimate cytotoxicity, as this has been shown to underestimate 
cytotoxicity less than some other measures such as relative cell counts (30). All CB samples exposed to all 
agents, had a calculated viability of greater than 75% at all time points analysed. HS-5 RICC were greater than 
75% following exposure to all agents over a 3hr period (Figure 3C). RICC above 70% was maintained after 
48hr exposure except where cells were exposed to S9 and S9/CY, with values of 24% and 31% respectively 
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(Figure 3C and 3D). Even after removal of this treatment, cell recovery following exposure to S9 alone was 
poor, and viability of cells exposed to a combination of CY and S9 decreased further over the next 48hrs (Figure 
4G). Therefore, it should be acknowledged that genotoxicity tests performed on HS-5 after 48hr treatment with 
S9 alone or in combination, will have been compounded by these high levels of cell death. 
Confirmation of the nature of DNA lesions present in these cells could be achieved by a larger study 
utilising the FLARE assay, and methods developed by Spanswick and colleagues for crosslink quantitation 
(34,46). Clinically, persisting DNA lesions may have important ramifications, therefore, preliminary data was 
gathered concerning genotoxic effects after in vivo chemotherapeutic treatment.  
Genotoxicity from in-vivo treatment 
Considerable increases in genotoxicity were seen following exposure to chemotherapeutic agents in 
vivo. This is particularly evident in samples from the same individual pre- and post-chemotherapy (p<0.001), 
treated with only 2 cycles of chemotherapy, the last of which was received one year prior to harvesting BM 
from which these cells were isolated (UPI 150/193). The vast majority of DNA damage is detected and repaired 
within 24 hours; therefore, if damage is still present one year after ceasing treatment, this would suggest it is 
highly likely to be long-term if not permanent, with damage tolerance pathways playing a role in maintaining 
the cellular population. 
Similarly, two patients who completed their chemotherapy 7 and 17 years prior to this analysis were 
compared with age- and sex-matched untreated individuals. Greater damage was seen in treated individuals 
(p<0.05), although inter-individual variation was also seen. The differences observed in these patients were less 
marked than the individual assessed pre- and post-chemotherapy, possibly due to inability to test pre- vs. post-
treatment samples limiting direct comparison and exacerbating inter-individual differences. Also, the extended 
timescale may reflect gradual loss of lesions, or through “dilution” due to cellular turnover. Finally, crosslinks 
may represent long-term persistent lesions and can retard DNA tails (46).  
Nevertheless, most recent treatment in all of these individuals was measured in years, strongly 
indicating the long-term nature and persistence of these genotoxic lesions. It is therefore likely that they are 
tolerated by the cell and are compatible with survival, but may increase risk of mutations and future 
malignancies, concurring with the increased risk of secondary malignancy seen in patients following 
chemotherapy (14,15,16,47). 
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Other than confirmation of no prior chemotherapy, it was not possible to obtain other clinical details 
from any of the individuals analysed. Clearly a diverse range of factors, including lifestyle and occupation will 
greatly impact on baseline levels of DNA damage, and will therefore contribute to inter-individual variation. 
Additionally, the chemotherapy treatment administered to treated patients varied, both in terms of agents used 
and numbers of cycles, and this will influence genotoxicity (see Table I).  
Haematopoietic cells in neonates and children have also been shown to have increased sensitivity to 
genotoxicity (48), with children treated with chemotherapy shown to have significantly increased MN 
frequencies in peripheral blood (49). Haematopoietic cells subsequently become less sensitive to MN formation 
with increasing age of the individual (48). Samples tested in this study were all from older adults, therefore there 
may be even more significant effects seen in individuals treated with chemotherapy at a young age, and 
consequently potentially a longer lifespan in which carcinogenesis can occur. 
Higher levels of genotoxicity in peripheral blood lymphocytes have previously been shown to be 
predictive of cancer risk, with MN formation thought to be associated with early carcinogenic events (50). 
Ideally, the patient samples in this study analysed by the comet assay would have also been assessed by MN 
assay, however, this was not possible due to low cell numbers obtained from chemotherapy-treated individuals. 
Clinical implication within the bone marrow 
For the first time, we show long-term genotoxic effects following chemotherapy in bone marrow 
stromal cells. Persisting aberrations have previously been detected in other haematological cell types following 
chemotherapy, with increased sister chromatid exchanges seen in peripheral blood lymphocytes up to 9 months 
after completion of therapy for breast cancer (21,22). Similarly, Lambert et al., (51) detected chromosomal 
aberrations in lymphocytes from ovarian cancer patients up to 10 years later, with 14% of individuals developing 
second primary tumours. However, another study reported that the majority of DNA base modifications in 
lymphocytes were repaired within 24 hours, although the study examined oxidative damage primarily (52). 
Genotoxicity can also vary between tissues, with persisting chromosomal aberrations detected in rat 
lymphocytes for up to 20 weeks after CY treatment, whereas clastogenic effects in BM were repaired within 
72hrs (53). A study by Yeh et al., (4) reported cytogenetic changes in BM MSC, but only in patients who were 
treated with both chemotherapy and radiotherapy, with no cytogenetic changes detected in patients treated with 
chemotherapy only. 
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Clinically, significant damage to the BM microenvironment may have a number of ramifications. 
Severe damage may result in increased apoptosis or senescence and consequently depletion of the stem cell 
pool. In haematopoietic stem cells this can manifest as clonal haematopoiesis (54,55), identified as a predictor 
of development of second primary malignancies (56,57). Potentially, this effect could also occur in the 
mesenchymal compartment. 
Surviving cells containing genetic lesions may also be affected functionally, which if occurring within 
MSC might significantly impact on haematopoiesis and ability to support a transplant. Failure to engraft occurs 
in up to 25% of SCTs, depending on stem cell source, conditioning regimen and recipient-donor disparity (12). 
Graft failure (GF) carries a dismal prognosis, with survival remaining very low in patients who undergo a second 
transplant. In a large study investigating 122 patients experiencing primary GF, following a second transplant 
overall one-year survival was only 11% (58). If links between engraftment and MSC health can be further 
studied, it may be possible to identify individuals most at risk of MSC damage and possible graft failure.  
Persistence of genetic aberrations/lesions can also lead to genetic instability and increased risk of 
developing a subsequent malignancy. This is currently a complication in up to 15% of chemotherapy-treated 
individuals, with many of these malignancies arising within the BM (15,59). Analysis of damage to the marrow 
microenvironment may allow identification of those at greatest risk, enabling dose-stratification or treatment 
modification to improve outcome and quality of life.  
The results presented here are only preliminary data gained on very small patient numbers; however, 
they provide strong indication of genotoxic lesions persisting within the BM following chemotherapy and 
warrant a large future study to confirm these effects. 
In conclusion, significant increases in genotoxicity were seen in supportive bone marrow cells following 
both in-vitro and in-vivo chemotherapeutic treatment. In vitro treatment at a clinically relevant dose induced 
genotoxicity that persisted for 48 hours after treatment removal, significantly, this is later than the point at which 
a stem cell transplant would be administered clinically, and may have important clinical implications. Genotoxic 
damage to BM MSC following in-vivo treatment appears to be a long-term effect, with significant damage 
persisting even 17 years after completion of therapy. Clinically, genotoxic damage to the BM microenvironment 
may have significant impacts on haematopoiesis, including ability to support a SCT, and increasing the risk of 
developing second primary malignancies.  
 22 
Funding 
This work was supported by an Early Career Pilot Study Grant from the UK Environmental Mutagenesis 
Society [JM] and a PhD studentship at the University of the West of England [JM]. 
Acknowledgements 
The authors would like to thank patients and staff at the Royal United Hospital, Bath, for donation and 
collection of bone marrow, and mothers and midwives at Southmead Hospital, Bristol for cord blood donation. 




1. Haylock,D.N, Williams,B, Johnston,H.M Liu,M.C, Rutherford,K.E, Whitty,G.A, Simmons,P.J, 
Bertoncello,I, and Nilsson,S.K, (2007) Hemopoietic Stem Cells with Higher Hemopoietic Potential Reside at 
the Bone Marrow Endosteum. Stem Cells, 25, 1062-1069   
2. Taichman,R.S, Reilly,M.J and Emerson,S.G. (1996) Human Osteoblasts Support Human Hematopoietic 
Progenitor Cells in In Vitro Bone Marrow Cultures. Blood, 87, 518-524  
3. Shipounova,I.N, Petinati,N.A, Bigildeev,A.E, Drize,N.J, Sorokina,T.V, Kuzmina,L.A, Parovichnikova,E.N, 
and Savchenko,V.G, (2017) Alterations of the bone marrow stromal microenvironment in adult patients with 
acute myeloid and lymphoblastic leukaemias before and after allogeneic hematopoietic stem cell 
transplantation. Leuk. Lymphoma, 58(2), 408-417 
4. Yeh,S, Lo,W, Lin,C, Liao,Y, Lin,C, Bai,L, Liang,J, and Chiu,C (2012) Anti-leukaemic therapies induce 
cytogenetic changes of human bone marrow-derived mesenchymal stem cells. Ann Hematol, 91, 163-172 
5. Kemp,K, Morse,R, Sanders,K, Hows,J, and Donaldson,C, (2011) Alkylating chemotherapeutic agents 
cyclophosphamide and melphalan cause functional injury to human bone marrow-derived mesenchymal stem 
cells. Ann Hematol, 90, 77-789 
6. De Lima Prata,K, Orellana,M.D, De Santis,G.C, Kashima,S, Fontes,A.M, Carrara,R, Palma,P.V, Neder,L, 
and Covas,D.T, (2010) Effects of high-dose chemotherapy on bone marrow multipotent mesenchymal stromal 
cells isolated from lymphoma patients. Exp. Hematol, 38, 292-300 
7. Kemp,K, Morse,R, Wexler,S, Cox,C, Mallam,E, Hows,J, and Donaldson,C, (2010) Chemotherapy-induced 
mesenchymal stem cell damage in patients with haematological malignancy. Ann Hematol, 89, 701-713  
8. Rieger,K, Marinets,O, Fietz,T, Korper,S, Sommer,D, Mucke,C, Reufi,B, Blau,W,I, Thiel,E, and Knauf,W.U, 
(2005) Mesenchymal stem cells remain of host origin even a long time after allogeneic peripheral blood stem 
cell or bone marrow transplantation. Exp. Hematol, 33, 605-611  
9. Laver,J, Jhanwar,S.C, O’Reilly, R.J, and Castro-Malaspina,H, (1987) Host origin of the Human 
Hematopoietic Microenvironment Following Allogeneic Bone Marrow Transplantation. Blood, 70, 1966-1968  
 24 
10. Le Blanc,K, and Ringden,O, (2005) Immunobiology of Human Mesenchymal Stem Cells and Future Uses 
in Hematopoietic Stem Cell Transplantation. Biol. Blood Marrow Tr, 11, 321-334 
11. Gallotto,M, Berisso,G, Delfino,L, Podesta,M, Ottagio,L, Dallorso,S, Dufour,C, Ferrara,G.B, 
Abbondandolo,A, Dini,G, Bacigalupo,A, Cancedda,R, and Quarto,R, (1999) Stromal damage as a consequence 
of high-dose chemo/radiotherapy in bone marrow transplant recipients. Exp Hematol, 27, 1460-1466  
12. Remberger,M, Mattsson,J, Olsson,R, and Ringden,O, (2011) Second allogeneic hematopoietic stem cell 
transplantation: a treatment for graft failure., Clin Transplant, 25(1), E68-76 
13. Popp, H.D, and Bohlander,S.K, (2010) Genetic Instability in Inherited and Sporadic Leukaemias. Genes, 
Chromosomes Cancer, 49, 1071-1081 
14. Imagawa,J, Harada,Y, Shimomura,T, Tanaka,H, Okikawa,Y, Hyodo,H, Kimura,A, and Harada,H, (2010) 
Clinical and genetic features of therapy-related myeloid neoplasms after chemotherapy for acute promyelocytic 
leukaemia. Blood, 116, 6018-6022  
15. Leone,G, Pagano,L, Ben-Yehuda,D, and Voso,M.T, (2007) Therapy-related leukaemia and myelodysplasia. 
Haematologica, 92, 1389-1398  
16. Dewail,V, Jais,J.P, Colonna,P, and Andrieu,J.M (2002) Fifteen-year secondary leukaemia risk observed in 
761 patients with Hodgkin’s disease prospectively treated by MOPP or ABVD chemotherapy plus high-dose 
irradiation. Br J. Haematol, 118, 189-194 
17. May,J.E, Morse,H.R, Xu,J, and Donaldson,C (2012) Development of a novel, physiologically relevant 
cytotoxicity model: Application to the study of chemotherapeutic damage to mesenchymal stromal cells. 
Toxicol. Appl. Pharmacol, 263, 374-389 
18. May,J, Morse,R, Xu,J, Avent,N, Febrey,S, Cox,C, Wexler,S, and Donaldson,C, (2011) Chemotherapy-
induced damage to mesenchymal stem cells: an in vitro model. Bone Marrow Transplant, 46(supplement 1), 
308 
19. Sorokina,T, Shipounova,I, Bigildeev,A, Petinati,N, Drize,N, Turkina,A, Chelysheva,E, Shukhov,O, 
Kuzmina,L, Parovichnikova,E, and Savchenko,V, (2015) The ability of multipotent mesenchymal stroma cells 
 25 
from the bone marrow of patients with leukaemia to maintain normal hematopoietic progenitor cells. Eur J. 
Hematol, 97, 245-252 
20. Buttiglieri,S, Ruella,M, Risso,A, Spatola,T, Silengo,L, Avvedimento,E.V, and Tarella,C, (2011) The ageing 
effect of chemotherapy on cultured human mesenchymal stem cells. Exp Hematol, 39, 1171-1181 
21. Vaghef,H, Nygren,P, Edling,C, Bergh,J, and Hellman,B, (1997) Alkaline single-cell electrophoresis and 
human biomonitoring for genotoxicity: a pilot study on breast cancer patients undergoing chemotherapy 
including cyclophosphamide. Mutation Res-Gen Tox. En, 395, 127-138  
22. Tucker,J.D, Wyrobek,A.J,Ashworth,L.K, Christensen,M.L, Burton,G.V, Carrano,A.V, and Everson,R.B, 
(1990) Induction, Accumulation, and Persistence of Sister Chromatid Exchanges in women with Breast Cancer 
Receiving Cyclophosphamide Adriamycin, and 5-Fluorouracil Chemotherapy. Cancer Res, 5, 4951-4956  
23. Guillaumet-Adkins, A, Yanez, Y, Peris-Diaz, M.D, Calabria, I, Palanca-Ballester, C and Sandoval, J (2017). 
Epigenetics and Oxidative Stress in Aging. Oxid Med Cell Longev. EPub ahead of print. doi: 
10.1155/2017/9175806 
24. Wexler,S.A, Donaldson,C, Denning-Kendall,P, Rice,C, Bradley,B, and Hows,J, (2003) Adult bone marrow 
is a rich source of human mesenchymal ‘stem’ cells but umbilical cord blood and mobilized adult blood are not. 
Br J. Haematol, 121, 368-374  
25. Pittenger,M.F, Mackay,A.M, Beck,S.C, Jaiswal,R.K, Douglas,R, Mosca,J, Moorman,M.A, Simonetti,D.W, 
Craig,S, and Marshak,D.R, (1999) Multilineage Potential of Adult Human Mesenchymal Stem Cells. Science, 
284, 143-147  
26. Dominici,M, Le Blanc,K, Mueller,I, Slaper-Cortenbach,I, Marini,F.C, Krause,D.S, Deans,R, Keating,A, 
Prockop,D.J, and Horwitz,E, (2006) Minimum criteria for defining multipotent mesenchymal stromal cells. The 
International Society for Cellular Therapy position statement. Cytotherapy, 8, 315-317 
27. Kirsch-Volders,M, Decordier,I, Elhajouji,A, Plas,G, Aardema,M,J and Fenech,M, (2011). In vitro 
genotoxicity testing using the micronucleus assay in cell lines, human lymphocytes and 3D human skin models. 
Mutagenesis, 26, 177-184 
 26 
28. Ringdén,O, and LeBlanc,K, (2005) Allogeneic hematopoietic stem cell transplantation: state of the art and 
new perspectives. APMIS 113, 813-30  
29. Ku,W.W, Bigger,A, Brambilla,G, Glatt,H, Gocke,E, Guzzie,P.J, et al., (2007) Strategy for genotoxicity 
testing – Metabolic considerations. Mutat. Res, 627, 59-77  
30. Fellows,M.D, O’Donovan,M.R, Lorge,E and Kirkland,D (2008). Comparison of different methods for an 
accurate assessment of cytotoxicity in the in vitro micronucleus test. II: Practical aspects with toxic agents. 
Mutat Res, 655, 4-21 
31. Xu,J, Ma,M, and Purcell,W.M, (2003) Characterization of some cytotoxic endpoints using rat liver and 
HepG2 spheroids as in vitro models and their application in hepatotoxicity studies. I. Glucose metabolism and 
enzyme release as cytotoxic markers. Toxicol. Appl. Pharmacol. 189, 100-111 
32. Tice,R.R, Agurell,E, Anderson,D, Burlinson,B, Hartman,A, Kobayashi,H, Miyamae,Y, Rojas,E, Ryu,J.C, 
and Sasaki,Y.F, (2000) Single Cell Gel/Comet Assay: Guidelines for In Vitro and In Vivo Genetic Toxicology 
Testing. Environ Mol Mutagen, 35, 206-211  
33. Anderson,D, Bishop,J.B, Garner,R.C, Ostrosky-Wegman,P, and Selby,P, (1995) Cyclophosphamide: 
Review of its mutagenicity for an assessment of potential germ cell risks. Mutat. Res, 330, 115-181  
34. Spanswick,V.J, Hartley,J.M, Ward,T.H, and Hartley,J.A, (1999) Measurement of Drug-Induced DNA 
Interstrand Crosslinking Using the Single-Cell Gel Electrophoresis (Comet) Assay. Methods in Mol Med, 28, 
143-154   
35. Oshida,K, Iwanaga,E, Miyamoto,K, and Miyamoto,Y, (2010) Comet assay in murine bone-marrow cell line 
(FDC-P2). Toxicol. In Vitro, 24, 1039-1044  
36. Cox,J.A, Fellows,M.D, Hashizume,T and White,P.A, (2016). The utility of metabolic activation mixtures 
containing human hepatic post-mitochondrial supernatant (S9) for in vitro genetic toxicity assessment. 
Mutagenesis, 31, 117-130 
37. Yang,S.E, Ha,C.W, Jung,M.H, Jin,H.J, Lee,M.K, Song,H.S, Choi,S, Oh,W, and Yang,Y.S, (2004) 
Mesenchymal stem/progenitor cells developed in cultures from UC blood. Cytotherapy, 6, 476-486 
 27 
38. Nicolay,N.H, Ruhle,A, Lopez Perez,R, Trinh,T, Sisombath,S, Weber,K, Schmexer,P, Ho,A.D, Debus,J, 
Saffrich,R, and Huber,P,E, (2016). Mesenchymal stem cells exhibit resistance to topoisomerase inhibition. 
Cancer Lett, 374, 75-84  
39. Schmidmaier,R, Baumann,P and Meinhardt,G (2006). Cell-cell contact mediated signalling – no fear of 
contact. Exp Oncol, 28, 12-15 
40. Utani K, Kohno Y, Okamoto A and Shimizu N, (2010). Emergence of Micronuclei and Their Effects on the 
Fate of Cells under Replication Stress. PLoS One. 5(4): 310089 
41. Araldi,R.P, Correa de Melo,T, Mendes,T.B, Luiz de Sa Junior,P, Nozima,B.H.N, Ito,W.T, Franco de 
Carvalho,R, Barreiros de Souza,E, Cassia Stocco,R. (2015). Using the comet and micronucleus assays for 
genotoxicity studies: A review. Biomed Pharmacother, 72, 74-82 
42. American Type Culture Collection (ATCC) HS-5 Datasheet (2016). HS-5 (ATCC CRL-11882). Available 
from: https://www.lgcstandards-atcc.org/Products/All/CRL-11882.aspx?geo_country=gb [Accessed 19 May 
2017] 
43. Brendler-Schwaab,S, Hartmann,A, Pfuhler,S, and Speit,G, (2005). The in vivo comet assay: use and status 
in genotoxicity testing. Mutagenesis, 20, 245-254 
44. Crook,T.R, Souhami,R.L, and McLean,A.E.M, (1986) Cytotoxicity, DNA Cross-Linking and Single Strand 
Breaks Induced by Activated Cyclophosphamide and Acrolein in Human Leukaemia Cells. Cancer Res, 46, 
5029-5034 
45. Koppen,G, Azqueta,A, Pourrut,B, Brunborg,G, Collins,A,R and Langie,S.A.S (2017). The next three 
decades of the comet assay: a report of the 11th International Comet Assay Workshop. Mutagenesis, 32, 397-
408 
46. Spanswick,V.J, Hartley,J.M, and Hartley,J.A, (2010) Measurement of DNA Interstrand Crosslinking in 
Individual Cells Using the Single Cell Gel Electrophoresis (Comet) Assay. Methods in Mol Med, 613, 267-282 
47. Yamamoto,K, Sada,A, Kawano,Y, Katawama,Y, Shimoyama,M, and Matsui,T, (2010) Therapy-related, 
mixed phenotype acute leukaemia with t(1;21) (p36;q22) and RUNX1 rearrangement. Cancer Genet. Cytogenet, 
201, 122-127  
 28 
48. Udroiu,I and Sgura,A (2016). Genotoxic sensitivity of the developing hematopoietic system. Mutat Res, 
767, 1-7  
49. Holland,N, Fucic,A, Merlo,D.F, Sram,R and Kirsch-Volders,M (2011). Micronuclei in neonates and 
children: effects of environmental, genetic, demographic and disease variables. Mutagenesis, 26, 51-56 
50. Bonassi,S, El-Zein,R, Bolognesi,C and Fenech,M, (2011). Micronuclei frequency in peripheral blood 
lymphocytes and cancer risk:evidence from human studies. Mutagenesis, 26, 93-100 
51. Lambert,B, and Holmberg,K, (1986) Chromosome Damage and Second Malignancy in Patients Treated 
with Melphalan. IARC Scientific Publications, 78, 147-160  
52. Olinski,R, Jaruga,P, Foksinski,M, Bialkowski,K, and Tujakowski,J, (1997) Epirubicin-Induced Oxidative 
DNA Damage and Evidence for Its Repair in Lymphocytes of Cancer Patients Who Are Undergoing 
Chemotherapy. Mol. Pharmacol, 52, 882-885 
53. Rosselli,F, Zaccaro,L, Venturi,M, and Rossi,A.M, (1990) Persistence of drug-induced chromosome 
aberrations in peripheral blood lymphocytes of the rat. Mutat. Res, 232, 107-114    
54. Mach-Pascual,S, Legare,R.D, Lu,D, Kroon,M, Neuberg,D, Tantravahi,R, Stone,R.M, Freedman,A.S, 
Nadler,L.M, Gribben,J.G, and Gilliland,D.G, (1998) Predictive value of clonality of assays in patients with non-
Hodgkin’s lymphoma undergoing autologous bone marrow transplant: a single institution study. Blood, 91, 
4496-4503  
55. Fern,L, Pallis,M, Carter,G.I, Seedhouse,C, Russell,N, and Byrne,J, (2004) Clonal haematopoiesis may occur 
after conventional chemotherapy and is associated with accelerated telomere shortening and defects in the 
NQO1 pathway; possible mechanisms leading to an increased risk of t-AML/MDS. Br J Haematol, 126, 63-71  
56. Legare,R.D, Gribben,J.G, Maragh,M, Hermanowshki-Vosatka,A, Roach,S, Tantravahi,R, Nadler,L.M, and 
Gilliland,D.G, (1997) Prediction of Therapy-Related Acute Myelogenous Leukaemia (AML) and 
Myelodysplastic Syndrome (MDS) After Autologous Bone Marrow Transplant (ABMT) for Lymphoma. Am J 
Hematol, 56, 45-51 
57. Gale,R.E, Bunch,C, Moir,D.J, Patterson,K.G, Goldstone,A.H, and Linch,D.C, (1996) Demonstration of 
developing myelodysplasia/acute myeloid leukaemia in haematologically normal patients after high-dose 
 29 
chemotherapy and autologous bone marrow transplantation using x-chromosome inactivation patterns. Br J 
Haematol, 93, 53-8  
58. Schriber,J, Agovi,M, Ho,V, Ballen,K.K, Bacigalupo,A, Lazarus,H.M, Bredeson,C.N, Gupta,V, 
Maziarz,R.T, Hale,G.A, Litzow,M.R, Logan,B,Bornhauser,M, Giller,R.H, Isola,L, Marks,D.I, Rizzo,J.D, and 
Pasquini,M.C, (2010) Second Unrelated Donor Hematopoietic Cell Transplantation for Primary Graft Failure. 
Biol Blood Marrow Tr, 16, 1099-1106 
59. Majhail,N.S, (2008) Old and New Cancers after Hematopoietic-Cell Transplantation. Hematology American 
Society of Hematology Education Program, 142-149  
